Personalized Care for Advanced RCC
Expert Guidance and Resources to Personalize Care and Improve Outcomes for Patients With RCC

Released: January 22, 2021

Expiration: January 21, 2022

Brian A. Costello
Brian A. Costello, MD, MS

Activity

Progress
1
Course Completed

  1. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-5799.
  2. International Kidney Cancer Coalition. InfoHub. Available at: https://ikcc.org/infohub/?fwp_infohub-search=IMDC+criteria. Accessed January 12, 2021.
  3. Méjean A, Escudier B, Thezenas S, et al. 2018. CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—results of a phase III noninferiority trial. Program and abstracts of the 2018 American Society of Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, Illinois. Abstract LBA3.
  4. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417-427.
  5. Mitchell AP, Hirsch BR, Harrison MR, et al. Deferred systemic therapy in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015;13:e159-e166.
  6. Rini BI, Dorff TB, Elson P, et al. Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncol. 2016;17:1317-1324
  7. Courtesy of Dr. Michael Harrison, Duke University, publication in press
  8. Albiges L, Tannir NM, Burotto M, et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open. 2020;5:e001079.
  9. Powles T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020;21:1563-1573.
  10. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116-1127.
  11. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31:1030-1039.
  12. Choueiri TK, Powles T, Burotto M, et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Program and abstracts of the 2020 European Society for Medical Oncology Congress; September 19-21, 2020. Abstract 696O.
  13. Plimack ER, Rini BI, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Program and abstracts of the 2020 American Society of Clinical Oncology virtual annual meeting; May 29-31, 2020. Abstract 5001.
  14. Soulieres D, Plimack E, Rini B, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for metastatic renal cell carcinoma: outcomes by IMDC risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. Program and abstracts of the International Kidney Cancer Symposium; November 15-16, 2019; Miami, Florida. Poster.
  15. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20:1370-1385.
  16. ClinicalTrials.gov. Lenvatinib/everolimus or lenvatinib/pembrolizumab versus sunitinib alone as treatment of advanced renal cell carcinoma (CLEAR). Available at: https://clinicaltrials.gov/ct2/show/NCT02811861. Accessed January 12, 2021.
  17. ClinicalTrials.gov. Study of Cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced or metastatic renal cell carcinoma (COSMIC-313). Available at: https://clinicaltrials.gov/ct2/show/NCT03937219. Accessed January 12, 2021.
  18. ClinicalTrials.gov. Safety and efficacy study of pembrolizumab (MK-3475) as monotherapy in the adjuvant treatment of renal cell carcinoma post nephrectomy (MK-3475-564/KEYNOTE-564). Available at: https://clinicaltrials.gov/ct2/show/NCT03142334. Accessed January 12, 2021.
  19. ClinicalTrials.gov. A study comparing nivolumab, nivolumab in combination with ipilimumab and placebo in participants with localized kidney cancer who underwent surgery to remove part of a kidney (CheckMate 914). Available at: https://clinicaltrials.gov/ct2/show/NCT03138512. Accessed January 12, 2021.
  20. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
  21. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
  22. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931-1939.
  23. Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14:552-562.
  24. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814-1823.
  25. Motzer RJ, Escudier B, Powles T, et al. Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer. 2018;118:1176-1178.
  26. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-1813.
  27. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473-1482.
  28. Lee CH, Shah AY, Hsieh JJ, et al. Phase II trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC). Program and abstracts of the 2020 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract 5008.
  29. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148.
  30. Steven NM, Fisher BA. Management of rheumatic complications of immune checkpoint inhibitor therapy—an oncological perspective. Rheumatology (Oxford). 2019;58(suppl 7):vii29-vii39.
  31. Robert C. Educational Session: Checkpoint Inhibitor Immunotherapy. Program and abstracts of the 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, Illinois.
  32. Owen DH, Burkart J, Patel S, et al. Immune related adverse events across cancer types: incidence, risk factors, and survival. Program and abstracts of the ESMO 2018 Congress; October 19-23, 2020; Munich, Germany. Abstract 4304.
  33. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-1768.